g.beaulieu
Submits third-party assay reports on material purchased directly. Based in Vaasa.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
10
n=10
Annotations
0
n=0
Median purity submitted
99.09%
n=10
Suppliers covered
9
n=10
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041973 | Tirzepatide | AMB | AMB-2603-C5112 | Janoshik | 2026-Q3 | 98.29 | 3.43 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041702 | BPC-157 | TFS | TFS-{CAT}-9814 | Medutest | 2026-Q2 | 99.08 | 4.95 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042031 | SS-31 (Elamipretide) | HYB | HYB-2512-B6579 | Janoshik | 2026-Q2 | 99.36 | 1.56 | 101.6 | Buyer-sourced | 0 | PASS |
| AX-2025-020451 | Melanotan II | KP | KP-2508-J5271 | PeptideMeter | 2025-Q3 | 98.16 | 6.34 | 89.1 | Buyer-sourced | 1 | FAIL |
| AX-2025-020573 | Tirzepatide | SSA | SSA-2502-D7226 | Janoshik | 2025-Q3 | 97.89 | 6.94 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019106 | Retatrutide | GSP | GSP-2411-B2857 | Janoshik | 2025-Q2 | 97.58 | 7.19 | 104.1 | Buyer-sourced | 0 | PASS |
| AX-2025-018805 | Exenatide | FGP | FGP-2504-V8032 | Janoshik | 2025-Q2 | 99.10 | 4.18 | 106.7 | Laboratory-retained | 0 | PASS |
| AX-2025-018907 | CJC-1295 with DAC | TFS | TFS-{CAT}-1220 | Janoshik | 2025-Q2 | 99.27 | 4.97 | 103.6 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-018414 | Semaglutide | WWB | WWB-2502-W1846 | Kestrel | 2025-Q1 | 99.79 | 5.75 | 103.3 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-018665 | Tirzepatide | QSC | QSC-2410-R5814 | PeptideMeter | 2025-Q1 | 99.83 | 5.00 | — | Buyer-sourced | 0 | PASS |